Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Molecular Cancer|December 4, 2023
Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemiaNuria Tubío-Santamaría, Ashok Kumar Jayavelu, Tina M Schnoeder, et al.
Nature|March 16, 2023
MEN1 mutations mediate clinical resistance to menin inhibitionFlorian Perner, Eytan M Stein, Daniela V Wenge, et al.
Nature|November 26, 2020
Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasmsAshok Kumar Jayavelu, Tina M Schnöder, Florian Perner, et al.
Cancer Cell|December 11, 2019
A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged LeukemiaAndrei V Krivtsov, Kathryn Evans, Jayant Y Gadrey, et al.
Biorxiv : the Preprint Server for Biology|December 23, 2024
Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemiaShellaina J V Gordon, Florian Perner, Laura MacPherson, et al.
Cancer Discovery|June 19, 2025
Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemiaShellaina J V Gordon, Florian Perner, Laura MacPherson, et al.
Blood|October 25, 2021
PLCG1 is required for AML1-ETO leukemia stem cell self-renewalTina M Schnoeder, Adrian Schwarzer, Ashok Kumar Jayavelu, et al.
Blood|October 27, 2025
Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AMLViktor Fetsch, Lennard Frederik Schwöbel, Ezgi Ozyerli-Goknar, et al.
Blood|June 21, 2024
Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemiasMin Chul Kwon, Jan Willem Thuring, Olivier Querolle, et al.
Pageof 4